Zydus received FDA approval to conduct a Phase 2b trial testing usnoflast, its oral therapy for ALS, in 210 patients.

The #ALS space—and the HEALEY ALS Platform Trial—saw two more failures this week, from Denali Therapeutics and AbbVie/Calico Life Sciences. After a disappointing 2024 for the space ...

Denali Therapeutics DNLI has performed well in the past 12 months amid a volatile market. Shares of the company have gained ...

The multi-centre, placebo-controlled, double-blind trial will assess the therapy’s safety, pharmacodynamics, efficacy, and pharmacokinetics in adult ALS patients. Sean M Healey & AMG Centre for ...

The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb ...

Delve into the increasingly dynamic landscape of ALS treatment development with thirteen companies advancing candidates in ...

Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease that remains incurable, despite decades of basic and clinical research. Key stakeholders—including the US National ...

Chelsee Healey has exited 'Dancing on Ice'. The 36-year-old actress has left the ITV show after she was revealed to be the celebrity with the fewest public votes. Chelsee was visibly upset by her ...

The trial of the Duke of Sussex's case against the Rupert Murdoch-owned tabloid 'The Sun' is set to begin in front of a judge in London on Jan. 21 Simon Perry is a writer and correspondent at PEOPLE.

The turn of events spelt the end for one notable competitor as Chelsee Healey found herself leaving the series. Upon her exit, Chelsee commented while holding back tears: "It's fine." Holly ...